Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of a SARS-CoV-2 mRNA vaccine in healthy adults aged 60 years and older
ChiCTR2100049521Phase 2Not yet recruiting
- Sponsor
- Shanxi Center for Disease Control and Prevention
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of LVRNA021 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shanxi Center for Disease Control and Prevention. Primary endpoints: IgG antibody, Neutralizing antibody and 1 more. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100049521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049521.